NextFin News - Merck reported first-quarter results on Thursday that exceeded Wall Street expectations, driven by the enduring dominance of its cancer immunotherapy Keytruda and a promising start for its newly launched cardiovascular drug, Winrevair. The pharmaceutical giant posted revenue of $16.29 billion, a 5% increase from the previous year, comfortably surpassing the $15.82 billion anticipated by analysts surveyed by LSEG. Despite a net loss of $4.24 billion, or $1.72 per share, the company attributed the deficit to a one-time $3.62 per share charge related to its acquisition of Cidara Therapeutics.
Keytruda remains the undisputed engine of Merck’s portfolio, generating $8.03 billion in quarterly sales, a 12% jump that beat the $7.78 billion consensus. The growth was fueled by increased adoption in earlier-stage cancer treatments and sustained demand for metastatic indications. Notably, the injectable version of Keytruda, a critical component of Merck’s strategy to defend its franchise against upcoming patent expirations, contributed $128 million in its first full year of availability. This formulation is designed to retain market share when the original intravenous version loses patent protection in 2028.
The quarter also marked the commercial debut of Winrevair, a treatment for pulmonary arterial hypertension that Merck acquired through its $11.5 billion purchase of Acceleron Pharma. Winrevair generated $245 million in its first few months on the market, signaling a robust launch for a product Merck hopes will eventually generate multi-billion dollar annual returns. This performance provided the confidence for management to narrow its full-year 2026 sales guidance to a range of $65.8 billion to $67 billion, while nudging its adjusted profit outlook upward to between $5.04 and $5.16 per share.
However, the transition away from older blockbusters is not without friction. Sales of the diabetes treatment Januvia fell 15% to $670 million as it faces intensifying generic competition and pricing pressure. This decline serves as a reminder of the "patent cliff" risks that haunt the sector. While Keytruda’s growth currently masks these weaknesses, the company is in a race to diversify its pipeline before its primary revenue driver loses exclusivity. The acquisition of Cidara Therapeutics, which triggered the quarterly loss, is part of this broader effort to secure new growth pillars in infectious diseases and beyond.
Market reaction remained cautiously optimistic as investors weighed the strength of the oncology business against the looming 2028 deadline. Some analysts have expressed concern that Merck’s reliance on Keytruda—which now accounts for nearly half of its total revenue—creates a concentration risk that even successful launches like Winrevair may struggle to fully offset. For now, the company’s ability to beat estimates and raise guidance suggests that its immediate operational execution remains sharp, even as the long-term structural challenges of the pharmaceutical industry begin to tighten their grip.
Explore more exclusive insights at nextfin.ai.
